Iron dysregulation in Huntington's disease
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is one of many neurodegenerative diseases with reported alterations in brain iron homeostasis that may contribute to neuropathogenesis. Iron accumulation in the specific brain areas of neurodegeneration in HD has been proposed based on observations in post‐mortem tissue and magnetic resonance imaging studies. Altered magnetic resonance imaging signal within specific brain regions undergoing neurodegeneration has been consistently reported and interpreted as altered levels of brain iron. Biochemical studies using various techniques to measure iron species in human samples, mouse tissue, or in vitro has generated equivocal data to support such an association. Whether elevated brain iron occurs in HD, plays a significant contributing role in HD pathogenesis, or is a secondary effect remains currently unclear. image Huntington's disease (HD) is one of many neurodegenerative diseases reported to have alterations in brain iron homeostasis. Whether elevated brain iron occurs in HD, and whether elevated iron levels play a significant contributory role in HD pathogenesis remains currently unclear. In this review, we discuss potential mechanisms by which mutant huntingtin‐mediated increases in intracellular calcium and elevated intracellular iron may interact to result in elevated levels of reactive oxygen species leading to lipid peroxidation, DNA damage, and neuronal cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947 · cited 1×
“Neurons are highly susceptible to free radical-mediated injury because of their requirement for high levels of oxidative metabolism and because neuronal membranes are rich in polyunsaturated fatty acids (Halliwell 1992).”
BackgroundThe ferritins: molecular properties, iron storage function and cellular regulation
Harrison, P. M., & Arosio, P. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00022-9 · Cited by 2,667
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Inflammation also induces cytokines that affect levels of hepcidin, the master regulator of iron in the body produced by liver (Krause et al. 2000; Park et al. 2001; Nemeth et al. 2004; De Domenico et al. 2010; Armitage et al. 2011).”
BackgroundRavikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324 · cited 1×
“Inflammation also induces cytokines that affect levels of hepcidin, the master regulator of iron in the body produced by liver (Krause et al. 2000; Park et al. 2001; Nemeth et al. 2004; De Domenico et al. 2010; Armitage et al. 2011).”
BackgroundGauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity
Lee, H.-K., Barbarosie, M., Kameyama, K., Bear, M. F., & Huganir, R. L. (2000) · Nature · doi:10.1038/35016089 · Cited by 1,116
Trinucleotide repeat length instability and age of onset in Huntington's disease
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089 · cited 2×
“The length of the expanded polyQ in HD inversely correlates with the age of onset (Duyao et al. 1993), accounting for ~70% of the variation, with a mean age onset at 40 years (Gusella and MacDonald 2009).”
BackgroundDEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Regulation of cellular iron metabolism
Wang, J., & Pantopoulos, K. (2011) · Biochemical Journal · doi:10.1042/bj20101825 · Cited by 986 · cited 1×
“Ferroportin is a ferroxidase and an important iron channel associated with iron export (Wang and Pantopoulos 2011).”
BackgroundTabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
Self-citationFerritins: A family of molecules for iron storage, antioxidation and more
Arosio, P., Ingrassia, R., & Cavadini, P. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.09.004 · Cited by 886 · cited 1×
“The iron storage protein ferritin can store up to 4500 iron atoms in a hollow sphere made up of 24 heavy (H) and light (L) chain subunits, that vary according to tissue distribution (Arosio et al. 2009).”
BackgroundBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease
Martinez-Vicente, M., Talloczy, Z., Wong, E., Tang, G., Koga, H., Kaushik, S., de Vries, R., Arias, E., Harris, S., Sulzer, D., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2528 · Cited by 885 · cited 1×
“In HD, there is diminished loading of autophagic vesicles, increased autophagosome levels, and polyQ-dependent changes in neuronal autophagy (Nagata et al. 2004; Martinez-Vicente et al. 2010; Zheng et al. 2010).”
BackgroundMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Chemistry and biology of eukaryotic iron metabolism
Aisen, P. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00063-2 · Cited by 804
Cu(II) Potentiation of Alzheimer Aβ Neurotoxicity
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37111 · Cited by 762
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · cited 1×
“Specifically, activity of the succinate dehydrogenase complex (CII) is reduced in the striatum in HD (Gu et al. 1996; Browne et al. 1997).”
BackgroundHuntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749 · cited 2×
“scriptional regulation, and clathrin-mediated endocytosis and exocytosis of vesicles at neurites and synapses (DiFiglia et al. 1995; Li et al. 2003).”
BackgroundNeural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis
Kasischke, K. A., Vishwasrao, H. D., Fisher, P. J., Zipfel, W. R., & Webb, W. W. (2004) · Science · doi:10.1126/science.1096485 · Cited by 742
Molecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh
Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., et al. (1995) · Science · doi:10.1126/science.7618107 · Cited by 723
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Mechanisms of mammalian iron homeostasis
Pantopoulos, K., Porwal, S. K., Tartakoff, A., & Devireddy, L. (2012) · Biochemistry · doi:10.1021/bi300752r · Cited by 598 · cited 3×
“Iron is an essential element that provides a wide range reduction-oxidation (redox) potential, ranging from +1000 mV to 550 mV depending on the ligand environment, which makes electron transfer possible for metabolic reactions to sustain life (Pantopoulos et al. 2012).”
BackgroundInfluentialTau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 2×
“iron accumulation, and parkinsonism pathology that can be prevented in mice using oral treatment with a moderate iron chelator, clioquinol (Lei et al. 2012).”
BackgroundWeydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562
A cytosolic iron chaperone that delivers iron to ferritin
Shi, H., Bencze, K. Z., Stemmler, T. L., & Philpott, C. C. (2008) · Science · doi:10.1126/science.1157643 · Cited by 536 · cited 1×
“Poly-binding proteins (PCBP1 and 2) are also known to target iron to ferritins (Shi et al. 2008).”
BackgroundRichardson, D. R., Lane, D. J. R., Becker, E. M., Huang, M. L.-H., Whitnall, M., Rahmanto, Y. S., Sheftel, A. D., & Ponka, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912925107 · Cited by 536
Regulation of iron transport and the role of transferrin
Gkouvatsos, K., Papanikolaou, G., & Pantopoulos, K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.10.013 · Cited by 518
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
Global changes to the ubiquitin system in Huntington's disease
Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K.-Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., & Kopito, R. R. (2007) · Nature · doi:10.1038/nature06022 · Cited by 497
Iron metabolism in the CNS: implications for neurodegenerative diseases
Rouault, T. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3453 · Cited by 496
Hepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466 · cited 1×
“Hepcidin is regulated at the transcriptional level, induced by iron, inflammation or ER stress (Ganz and Nemeth 2011).”
BackgroundMicroglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 4×
“Neuronal loss and astrogliosis proceed in a dorsomedial to ventrolateral direction resulting in striatal atrophy and an enlargement of lateral ventricles that associates with subclinical progression of disease (Albin and Tagle 1995; Pavese et al. 2006).”
BackgroundInfluentialGoehler, H., Lalowski, M., Stelzl, U., Waelter, S., Stroedicke, M., Worm, U., Droege, A., Lindenberg, K. S., Knoblich, M., Haenig, C., et al. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.016 · Cited by 453 · cited 2×
“The expanded mHtt polyQ tract results in a dysfunctional conformational flexibility of theN-terminal region of the protein, disrupting important protein–protein interactions (Metzler et al. 2001; Sun et al. 2001; Goehler et al. 2004; Giorgini and Muchowski 2005; Zuccato et al. 2010; Caron et al. 2013).”
BackgroundA human mitochondrial ferritin encoded by an intronless gene
Levi, S., Corsi, B., Bosisio, M., Invernizzi, R., Volz, A., Sanford, D., Arosio, P., & Drysdale, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100141200 · Cited by 400
Metal complexing agents as therapies for Alzheimer’s disease
Bush, A. I. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00120-3 · Cited by 310
Hepcidin regulation by innate immune and infectious stimuli
Armitage, A. E., Eddowes, L. A., Gileadi, U., Cole, S., Spottiswoode, N., Selvakumar, T. A., Ho, L.-P., Townsend, A. R. M., & Drakesmith, H. (2011) · Blood · doi:10.1182/blood-2011-04-351957 · Cited by 294
Qin, L., Liu, Y., Hong, J., & Crews, F. T. (2013) · Glia · doi:10.1002/glia.22479 · Cited by 271
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications
Bartzokis, G., Lu, P. H., Tishler, T. A., Fong, S. M., Oluwadara, B., Finn, J. P., Huang, D., Bordelon, Y., Mintz, J., & Perlman, S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9352-7 · Cited by 238
YOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233
Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles
Hilditch-Maguire, P. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2789 · Cited by 226
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation
Chinnery, P. F., Crompton, D. E., Birchall, D., Jackson, M. J., Coulthard, A., Lombes, A., Quinn, N., Wills, A., Fletcher, N., Mottershead, J. P., et al. (2006) · Brain · doi:10.1093/brain/awl319 · Cited by 205
De Domenico, I., Zhang, T. Y., Koening, C. L., Branch, R. W., London, N., Lo, E., Daynes, R. A., Kushner, J. P., Li, D., Ward, D. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42011 · Cited by 197 · cited 1×
“Inflammation also induces cytokines that affect levels of hepcidin, the master regulator of iron in the body produced by liver (Krause et al. 2000; Park et al. 2001; Nemeth et al. 2004; De Domenico et al. 2010; Armitage et al. 2011).”
BackgroundNguyen, T., Hamby, A., & Massa, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502177102 · Cited by 194
Increased basal ganglia iron levels in Huntington disease
Bartzokis, G., Cummings, J., Perlman, S., Hance, D. B., & Mintz, J. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.569 · Cited by 183
Huntington's disease: The current state of research with peripheral tissues
Sassone, J., Colciago, C., Cislaghi, G., Silani, V., & Ciammola, A. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.012 · Cited by 175 · cited 1×
“HD is mainly thought of as a CNS disorder, but abnormal cellular phenotypes have been described in fibroblasts, red and white blood cells, pancreatic, liver, muscle, cardiac cells, bones and testes, in culture or patient samples (Sassone et al. 2009).”
BackgroundBoll, M.-C., Alcaraz-Zubeldia, M., Montes, S., & Rios, C. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9610-3 · Cited by 173
Use of desferrioxamine in the treatment of aceruloplasminemia
Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., & Gitlin, J. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410318 · Cited by 173
Ross, S. L., Tran, L., Winters, A., Lee, K.-J., Plewa, C., Foltz, I., King, C., Miranda, L. P., Allen, J., Beckman, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.017 · Cited by 145
Rangone, H., Poizat, G., Troncoso, J., Ross, C. A., MacDonald, M. E., Saudou, F., & Humbert, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03131.x · Cited by 144 · cited 1×
“There are many PTM sites on Htt that lead to prosurvival pathways (Rangone et al. 2004; Luo et al. 2005; Warby et al. 2005; Schilling et al. 2006; Thompson et al. 2009).”
BackgroundMealer, R. G., Murray, A. J., Shahani, N., Subramaniam, S., & Snyder, S. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.536912 · Cited by 124
Magnetic resonance imaging of brain iron
Schenck, J. F. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00431-8 · Cited by 116
Bakshi, R., Dmochowski, J., Shaikh, Z. A., & Jacobs, L. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00477-4 · Cited by 107 · cited 1×
“…associated with iron deposition has been observed in various neurodegenerative diseases, including AD (Bartzokis and Tishler 2000), PD (Michaeli et al. 2007), and multiple sclerosis (MS) (Drayer et al. 1987; Grimaud et al. 1995; Bakshi et al. 2000, 2001; Nishii et al. 2000; Bermel et al. 2005).”
BackgroundGenetics of neurodegeneration with brain iron accumulation
Gregory, A., & Hayflick, S. J. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0181-3 · Cited by 104
MRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation
Bakshi, R., Shaikh, Z. A., & Janardhan, V. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00004 · Cited by 92 · cited 1×
“…associated with iron deposition has been observed in various neurodegenerative diseases, including AD (Bartzokis and Tishler 2000), PD (Michaeli et al. 2007), and multiple sclerosis (MS) (Drayer et al. 1987; Grimaud et al. 1995; Bakshi et al. 2000, 2001; Nishii et al. 2000; Bermel et al. 2005).”
BackgroundHuntingtin inclusion bodies are iron‐dependent centers of oxidative events
Firdaus, W. J. J., Wyttenbach, A., Giuliano, P., Kretz‐Remy, C., Currie, R. W., & Arrigo, A. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05537.x · Cited by 71
Cited by
Ferroptosis: Death by Lipid Peroxidation
Yang, W. S., & Stockwell, B. R. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.014 · Cited by 3,088
The development of the concept of ferroptosis
Hirschhorn, T., & Stockwell, B. R. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.043 · Cited by 1,052
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Elfawy, H. A., & Das, B. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.029 · Cited by 343
Metadata
- Authors
- Muller, M., & Leavitt, B. R.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2014-05-28
- Volume
- 130
- Issue
- 3
- Pages
- 328-350
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2064636913
- Cited by
- 124
- References
- 62
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.